With a simple blood test, we can help

Pharma companies rely
on us

Our pharma partner team includes clinical-, regulatory-, technology-, and pharma-collaboration expertise; we are happy to share our knowledge.

Why do Pharma companies work with Biovica?

Our liquid (serum/plasma samples) TKa-biomarker assay measures thymidine kinase activity (TKa) which reflects tumor cell proliferation. The biomarker assay is used by pharma in the following ways:

  • TKa for upfront selection of patients for a specific treatment
  • TKa for early on-treatment monitoring and selection of patients for a specific treatment
  • TKa for on-treatment monitoring of continued response to specific drug

Our pharma-partner team has your needs in mind, offering services and collaborations in pre-clinical, clinical, and companion diagnostic (CDx) initiatives. The team includes clinical, regulatory, and technology expertise.

We focus on a complete assay system solution from laboratory workflow and assay robustness to assay distribution and support. Optimizing assay turn-around-time (TAT) and hands-on-time (HOT) as well as global registration and distribution are in our team’s DNA.

Pharma/biotech services and collaborations:
CDx + Rx co-development with the DiviTum®️ TKa test

Pre-clinical, Phase I/II: Biovica operates as a fee-for-service R&D partner to Oncology Pharma, offering the DiviTum®️ TKa test as a collaborative tool, including:

  • Individualized guidance and planning of TKa inclusion in clinical studies
  • Execution of TKa testing in certified labs
  • Analyses of TKa test results
  • Discussion of results

Phase II/III: Biovica offers CDx co-development, IVD registration, and commercialization.

Oncologists see the value

What oncologists say

Professor Daniel Hayes MD
These results should serve as the basis for future clinical studies to distinguish patients with estrogen receptor-positive metastatic breast cancer who might be best treated with endocrine therapy alone.
Professor Daniel F. Hayes MD
University of Michigan Rogel Cancer Center
img-cynthia-ma-1
Our results imply that DiviTum®️ TKa is prognostic both at baseline and on treatment with CDK4/6 inhibitors.
Cynthia Ma, MD, PhD
Professor of Medicine and medical oncologist Division of Medical Oncology, Washington University, St. Louis.
Dr. Luca Malorni
These results are highly encouraging and highlight the potential of DiviTum®️ TKa to evaluate treatment efficacy already during the first weeks of therapy, and afterwards to monitor the disease.
Dr. Luca Malorni
Principal Investigator of the Study at Prato Hospital, Italy
Dr. Jairam Krishnamurthy
The results from our study support using DiviTum®️ TKa to monitor efficacy during treatment and predict response to palbociclib, a standard therapy for women with metastatic breast cancer.
Dr. Jairam Krishnamurthy
Principal Investigator of the Study at Division of Oncology/Hematology, University of Nebraska Medical Center

Patients are at the center of everything we do

Contact your doctor to see if you are eligible for DiviTum®️TKa testing

Some of our Collaborations

>3200

Numbers of patients in studies

24

Publications

10

Pharma Contracts